Sirtuin 6 inhibition protects against glucocorticoid-induced skeletal muscle atrophy by regulating IGF/PI3K/AKT

Sneha Mishra1, Claudia Cosentino2, Ankit Kumar Tamta1

  • 1Department of Microbiology and Cell Biology, Indian Institute of Science, Bengaluru, India.

Nature Communications
|September 15, 2022
PubMed

Insights

SIRT6 protein levels increase during muscle wasting caused by glucocorticoids. Reducing SIRT6 protects muscles by enhancing protein synthesis and blocking atrophy, revealing SIRT6 as a key regulator of glucocorticoid-induced muscle atrophy.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Physiology

Background:

  • Chronic stress hormone activation, like glucocorticoids, causes skeletal muscle wasting.
  • The precise molecular mechanisms behind glucocorticoid-induced muscle atrophy remain unclear.

Purpose of the Study:

  • To investigate the role of SIRT6, a chromatin-associated deacetylase, in glucocorticoid-induced skeletal muscle wasting.
  • To elucidate the molecular pathways modulated by SIRT6 in muscle atrophy.

Main Methods:

  • Assessed SIRT6 expression during glucocorticoid treatment and in mouse models of muscle atrophy.
  • Utilized cell-autonomous overexpression and depletion of SIRT6 in primary myotubes.
  • Generated muscle-specific SIRT6 deficient mice.
  • Investigated the impact of pharmacological SIRT6 inhibition.

Main Results:

  • SIRT6 levels rise with glucocorticoid-induced myotube atrophy and in mouse skeletal muscle atrophy.
  • SIRT6 depletion enhances myotube diameter, protein synthesis, and represses atrogenes, conferring protection against glucocorticoid-induced wasting.
  • Muscle-specific SIRT6 deficient mice exhibit resistance to glucocorticoid-induced muscle wasting.
  • SIRT6 deficiency activates IGF/PI3K/AKT signaling via increased IGF2 expression, leading to FoxO transcription factor repression.

Conclusions:

  • SIRT6 plays a critical role in mediating glucocorticoid-induced skeletal muscle wasting.
  • Modulating SIRT6 activity, particularly through pharmacological inhibition, offers a potential therapeutic strategy against muscle atrophy.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.9K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.2K